Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/ metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment

被引：0
|
作者：
Jove, M. [1 ]
Brana, I. [2 ,3 ]
Oliva Bernal, M. [4 ]
Hernando Calvo, A.
Erasun Lecuona, C. [4 ]
Assaf Pastrana, J. D. [2 ,3 ]
Mato-Berciano, A. [5 ]
V. Maliandi, M. [5 ]
Torres-Manjon, S. [6 ]
Moreno, R. [6 ]
Le, C. [7 ]
G. Nuciforo, P. [8 ]
Alemany, R. [6 ]
Capella, G. [9 ]
Blasco, C. [10 ]
Cascallo Piqueras, M. [10 ]
Mesia Nin, R. [11 ]
机构：
[1] Catalan Inst Oncol ICO, Med Oncol Phase Funct Unit 1, Lhospitalet De Llobregat, Spain
[2] Vall dHebron Hosp Univ, Med Oncol Dept, Barcelona, Spain
[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[4] Catalan Inst Oncol ICO, Med Oncol Phase Funct Unit 1, Barcelona, Spain
[5] Theriva Biol, R&D, Parets Del Valles, Spain
[6] ICO Inst Catala Oncol Hosp Duran I Reynals, IDIBELL, ProCure Program ICO Program Mol Mech & Expt Ther, Lhospitalet De Llobregat, Spain
[7] Theriva Biol, Stat & Analyt, Rockville, MD USA
[8] Vall dHebron Inst Oncol VHIO Cellex Ctr, Mol Oncol Dept, Barcelona, Spain
[9] IDIBELL, Program Mol Mech & Expt Therapy Oncol Oncobell, Lhospitalet De Llobregat, Spain
[10] Theriva Biol, Clin Operat, Parets Del Valles, Spain
[11] IGTP, ICO Inst Catala Oncol, Med Oncol Dept, B ARGO Grp, Badalona, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
937P
引用
收藏
页码：S589 / S590
页数：2
相关论文
共 50 条
  • [21] Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial
    Ching-Yun Hsieh
    Ming-Yu Lien
    Chen-Yuan Lin
    Wen-Jyi Lo
    Chung-Hung Hua
    Wei-Chao Chang
    Chang-Fang Chiu
    Ching-Chan Lin
    BMC Cancer, 22
  • [22] Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
    Gulati, Shuchi
    Crist, McKenzie
    Riaz, Muhammed Kashif
    Takiar, Vinita
    Lehn, Maria
    Monroe, Ilaina
    Palackdharry, Sarah
    Kurtzweil, Nicky
    Jandarov, Roman
    Harun, Nusrat
    Wise-Draper, Trisha M.
    CLINICAL CANCER RESEARCH, 2023, 29 (10) : 1906 - 1915
  • [23] A phase I trial of prolonged administration of lovastatin inpatients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) or of the cervix (CC).
    Knox, JJ
    Siu, LL
    Kamel-Reid, S
    Dimitroulakos, J
    Moore, MJ
    Lumb, K
    Irish, J
    La Framboise, S
    Gullane, P
    Buchan, S
    Chin, S
    Oza, AM
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3723S - 3723S
  • [24] RAPTOR, the global phase II, III clinical development program of the PD-L1 inhibitor Durvalumab (MEDI4736) in 2nd-line recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) - A German update on the HAWK, EAGLE and CONDOR trials
    Ruessel, J.
    von Einem, J.
    Keilholz, U.
    Dietz, A.
    Gruenewald, V
    Maschmeyer, G.
    Kasper, S.
    Rupprecht, M.
    Sasse, B.
    Melillo, G.
    Krauss, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 173 - 174
  • [25] Phase II trial of combined durvalumab plus tremelimumab with proton therapy to boost the abscopal effect for recurrent or metastatic head and neck squamous cell carcinoma.
    Kim, Hana
    Ahn, Myung-Ju
    Oh, Dongryul
    Park, Sehhoon
    Jung, Hyun Ae
    Lee, Se-Hoon
    Park, Keunchil
    Ahn, Yong Chan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] A Phase II Trial of Personalized Immunotherapy in Patients (pts) with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC) That Have Progressed on Prior Immunotherapy
    Zandberg, D. P.
    Chen, J.
    Tatsuoka, C.
    Normolle, D. P.
    Ohr, J.
    Isett, B.
    Rahman, Z.
    Fenton, M.
    Gooding, W.
    Vujanovic, L.
    Bao, R.
    Marsh, C.
    Seastone, D.
    Gorantla, V.
    Pabla, S.
    Conroy, J.
    Ferris, R. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E4 - E4
  • [27] A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck
    Bossi, P.
    Merlano, M. C.
    Ghi, M. G.
    Rinaldi, G.
    Caponigro, F.
    Morelli, F.
    Airoldi, M.
    Farnesi, A.
    Cassano, A.
    Ferrari, D.
    Mirabile, A.
    Tosoni, A.
    Galizia, D.
    Moretti, G.
    Sponghini, A. P.
    Calareso, G.
    Vingiani, A.
    Perrone, F.
    Falletta, A.
    Licitra, L. F.
    ANNALS OF ONCOLOGY, 2019, 30 : 463 - 463
  • [28] A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic human papilloma virus-associated head and neck squamous cell cancer.
    Aggarwal, Charu
    Halmos, Balazs
    Porosnicu, Mercedes
    Saba, Nabil F.
    Sukari, Ammar
    Grethlein, Sara Jo
    Mehra, Ranee
    Adkins, Douglas
    Fidler, Mary J.
    Kumar, Rakesh
    Yang, Jie
    Abdullah, Shaad Essa
    Haigentz, Missak
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: A multicenter phase II trial
    Gebbia, V
    Mantovani, G
    Agostara, B
    Contu, A
    Farris, A
    Colucci, G
    Cognetti, F
    Restivo, G
    Speciale, R
    Ferrero, B
    Testa, A
    Curreli, L
    Cardinale, A
    Bajetta, E
    Gebbia, N
    ANNALS OF ONCOLOGY, 1995, 6 (10) : 987 - 991
  • [30] PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Rischin, Danny
    Spigel, David R.
    Adkins, Douglas
    Wein, Richard
    Arnold, Susanne
    Singhal, Nimit
    Lee, Oliver
    Murugappan, Swami
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 : E1756 - E1761
12345